Multicenter, retrospective, blinded validation study of 309 subjects with indeterminate thyroid nodules (Bethesda III, IV, or V) and corresponding surgical histology. Gold-standard unanimous consensus histopathology diagnosis (n=197) among three pathologists …
This paper discusses the development of an expanded mutation panel (ThyGeNEXT®). Additionally, it demonstrates the analytical validation of the expanded NGS panel test and compares analytical characteristics of ThyGeNEXT to the …
This multicenter prospective observational study evaluated the use of a mutation detection and miRNA expression algorithm to improve the diagnostic yield of molecular testing for thyroid nodules. 109 thyroid nodules …
This study evaluated the clinical performance of ThyGeNEXT®, an expanded mutation panel of strong and weak drivers of oncogenic changes, used in combination with ThyraMIR®, a microRNA classifier for the …
In this study, molecular results from 12,993 consecutive patient samples were reviewed for cases that either underwent testing with a focused mutation panel (n=8619) or an expanded mutation panel (ThyGeNEXT®, …
This multicenter, observational, real-world clinical experience study examined the likelihood of patients with indeterminate thyroid nodules to undergo surgery or have malignant outcomes based on multiplatform combination mutation and microRNA …
In this study, real-world clinical results of molecular testing for indeterminate thyroid nodules were analyzed based upon Bethesda categorization, mutation analysis, and microRNA classifier results and were correlated to show …
The purpose of this study was to determine the health outcome benefits and cost-effectiveness of molecular testing in nodules with AUS/FLUS or FN/SFN cytology. The initial diagnosis and treatment of …
This study was designed to determine if routinely prepared thyroid FNA cytology smears can be used for molecular profiling by NGS for oncogene mutations and oncogenic fusion transcripts, and by …
This study examined a comprehensive evaluation of miRNA gene expression in diverse thyroid lesions (n=534) and developed predictive models for the classification of thyroid nodules. miRNA-based classifiers complemented and significantly …
Interpace Diagnostics is a registered trademark and business unit of Interpace Biosciences, Inc.™
©2020 Interpace Biosciences, Inc.™ All rights reserved.
